Organogenesis Holdings Inc. (ORGO) is a Healthcare stock trading at $1.80 (as of 2026-08-21), with a market capitalization of $231.61M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Organogenesis develops, manufactures, and commercializes regenerative medicine products for advanced wound care plus surgical and sports medicine, generating money by selling these products (including Affinity, Apligraf, Dermagraft, and PuraPly) through its commercial channels in the United States.
The companys profit model is primarily driven by converting its commercial execution (direct sales coverage and office channel presence) into Net Product Revenue from its advanced wound care and related products, while clinical progress and regulatory clearances (such as Phase 3 enrollment and PureApply MZ clearances) determine what can expand future sales.
Business quality (Weak): Segment revenue breakdown is not useable here because the provided total revenue is 0.0B while the candidate segment revenues sum to a nonzero amount.
| Price | $1.80 |
| Market Cap | $231.61M |
| Price / Book | 1.56 |
| Price / Sales | 0.86 |
| FCF Yield | -16.4% |
| DCF Value (model) | $4.39 |
| DCF Upside vs Price | 143.9% |
| Revenue (TTM) | $564.17M |
| Net Margin | 6.6% |
| Revenue Growth (YoY) | 17.0% |
| EPS Growth (YoY) | -1700.0% |
| FCF Growth (YoY) | -685.7% |
| Altman Z-Score | 2.17 (grey) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | MORGAN STANLEY ($27.53M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Gary S. Gillheeney |
| Employees | 869 |
| Country | US |
| IPO Date | 2017-01-05 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.